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Abstract
Oral vaccination can offer a painless and convenient method of vaccination. Furthermore, in 
addition to systemic immunity it has potential to stimulate mucosal immunity through antigen-
processing by the gut-associated lymphoid tissues. In this study we propose the concept that pollen 
grains can be engineered for use as a simple modular system for oral vaccination. We demonstrate 
feasibility of this concept by using spores of Lycopodium clavatum (clubmoss) (LSs). We show 
that LSs can be chemically cleaned to remove native proteins to create intact clean hollow LS 
shells. Empty pollen shells were successfully filled with molecules of different sizes 
demonstrating their potential to be broadly applicable as a vaccination system. Using ovalbumin 
(OVA) as a model antigen, LSs formulated with OVA were orally fed to mice. LSs stimulated 
significantly higher anti-OVA serum IgG and fecal IgA antibodies compared to those induced by 
use of cholera toxin as a positive-control adjuvant. The antibody response was not affected by pre-
neutralization of the stomach acid, and persisted for up to seven months. Confocal microscopy 
revealed that LSs can translocate in to mouse intestinal wall. Overall, this study lays the 
foundation of using LSs as a novel approach for oral vaccination.
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1. Introduction
Oral vaccination is of significant interest because it is needle-free, painless, child-friendly, 
convenient, and amenable to self-administration. Furthermore, antigen delivery to the 
gastrointestinal tract has potential to induce mucosal immunity through antigen-processing 
via the gut-associated lymphoid tissues [1, 2]. Because majority of pathogens infect via 
mucosal surfaces, immunological defenses at mucosal surfaces can neutralize pathogens 
before they can cause infection [3].
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However, oral vaccination remains daunting because the vaccine molecules experience a 
highly degradative environment in the stomach, and encounter a tough transport barrier 
offered by the tightly juxtaposed epithelial cells that line the intestinal mucosa [4]. To 
overcome these delivery challenges, live attenuated microorganisms such as bacteria and 
viruses, and particulate vaccine delivery systems such as liposomes, virosomes, polymeric 
micro and nanoparticles, and immune stimulating complexes have been examined [5, 6]. 
Various techniques that seek to target microfold (M) cells to enable higher antigen uptake 
through endocytosis have also been tested [7]. Toxins such as cholera toxin (CT) and heat 
labile enterotoxin (LT) that enable increased uptake of vaccine molecules have demonstrated 
the highest adjuvant effects [8, 9]. However, the toxicity of CT and LT naturally renders 
them unsuitable for human use [10]. The dangers of attenuated yet live strains of viruses and 
bacteria to become virulent, or their neutralization through pre-existing host immunity are 
some of the limitations of using microorganisms for oral vaccination [11]. Additionally, low 
encapsulation efficiency of antigens in polymeric particles, and poor vaccine stability 
resulting from exposure to organic solvents during particle synthesis has hindered clinical 
use of polymeric particles [12]. Plant-based edible vaccines expressed in rice [13], tobacco, 
tomato, carrot and potato have also been investigated [14]. Based on a twenty year 
development experience of an edible vaccine against hepatitis B, it has been found that just 
oral administration of edible plant-based hepatitis vaccine was insufficient for a protective 
response, yet when coupled in an oral-parenteral dosage regimen, it proved to be effective 
[14].
In this study we propose a novel concept to use pollen grains (PGs) as a natural system for 
oral vaccination. In nature, PGs facilitate pollination by functioning as a ‘safety-pod’ to 
carry the plant male gamete to the female reproductive organ, the ovary, located in the 
flower. During pollination PGs are often exposed to fluctuating temperatures and weather 
conditions, and to survive such conditions, they possess mechanical toughness and chemical 
resistance. Our postulate to use PGs for oral vaccination is based on such multiple natural 
properties of PGs that suggest their usefulness for oral vaccination: (i) they have a tough 
outer shell that can stay intact in the stomach environment [15, 16], (ii) the shell is naturally 
porous, and (iii) despite their relatively large size (tens of μm in diameter) it has been found 
that Lycopodium clavatum (clubmoss) spores (LSs) and Secale cereale (rye) pollen grains 
can cross the intestinal barrier as intact particles [17, 18]. Thus overall, we hypothesized that 
if (i) natural pores in the pollen wall could be used to clean and remove the allergy-causing 
native biomolecules from PGs, (ii) their clean ‘belly’ could be refilled with vaccine antigens 
through the natural pores in pollen walls, and (iii) the antigen-filled PGs could translocate 
across the intestinal epithelium into the body, then PGs might behave as natural ‘Trojan 
horses’ for oral vaccination ferrying the vaccines safely into the body. While LSs can 
survive the harsh acidic treatment, it has been suggested that enzymes in the body can 
degrade them [18, 19], thus providing a potentially safe natural carrier for oral vaccine and 
drug delivery. Indeed, using this conceptual framework LSs have recently been proposed for 
oral drug delivery. It has been shown that proteins as large as 540 kDa, a magnetic 
resonance imaging contrast agent, food oils including cod liver oil can be filled into LSs 
[19-23]. While these in vitro studies demonstrate the flexibility of filling LSs with different 
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molecules, in vivo demonstrations on the effectiveness of pollens for oral drug and vaccine 
delivery are lacking.
Herein we demonstrate for the first time that LSs filled with ovalbumin (OVA) as a model 
antigen when fed orally to mice can induce a systemic and a mucosal immune response, 
which is superior to that stimulated by CT, a potent yet toxic mucosal adjuvant. We also 
investigated whether neutralization of stomach's acidic environment, prior to administration 
of the LS-based oral vaccine can affect the immune response. The durability of antigen-
specific systemic and mucosal antibodies was also investigated, and it was found that OVA-
specific antibodies could be detected in significant amounts up to seven months after 
vaccination. Overall this study lays the foundation for an oral vaccination platform that is 
simple to implement and has potential for applicability to a broad range of vaccines.
2. Materials and Methods
2.1. Pollens, chemicals, proteins and antibodies
LSs, dextran conjugated to fluorescein isothiocyanate (4000 Da and 2000 kDa), 
sulforhodamine (558 Da), and phosphate-citrate buffer tablets were purchased from Sigma-
Aldrich (MO, USA). Pollens of chenopodium album (lambs quarters), helianthus annuus 
(sunflower), artemisia vulgaris (mugwort), and alnus glutinosa (alder black) were obtained 
from Pharmallerga (Lišov, Czech Republic). Acetone, potassium hydroxide, 
orthophosphoric acid, ethanol, hydrochloric acid, sodium hydroxide and tween 20 were 
purchased from Fisher Scientific (PA, USA). O-phenylenediamine (OPD) was obtained 
from Invitrogen (NY, USA). Milli-Q water with a resistance of 18.2 MΩ.cm was used in all 
experiments. OVA was purchased from MP Biomedicals (OH, USA). CT and CTB were 
purchased from Sigma-Aldrich (MO, USA). Goat anti-mouse IgG, IgG1, IgG2a, IgA, and 
IgE with the horseradish peroxidase (HRP) conjugate were bought from Southern Biotech 
(AL, USA). Texas-red labeled OVA and bovine serum albumin were purchased from 
Invitrogen (OR, USA).
2.2. LS treatment and characterization
LSs were chemically treated to produce intact clean spores by modifying a previously 
published process [24]. Briefly, 50 g of dry LSs were stirred in 300 mL of acetone under 
reflux overnight. Following filtration and overnight drying, they were stirred under reflux in 
450 mL of 2M potassium hydroxide for 12h at 120 °C (renewed after 6h). They were then 
filtered and washed with hot water (5 × 300mL) and hot ethanol (5 × 300mL). After drying 
overnight, LSs were stirred under reflux for 7 days in 450mL of orthophosphoric acid at 180 
°C. LS were filtered and washed sequentially with water (5 × 300mL), acetone (300mL), 
2M HCl (300mL), 2M NaOH (300mL), water (5 × 300mL), acetone (300mL) and ethanol 
(300mL). Finally, they were dried at 60 °C until constant weight was achieved. The final 
protein concentration of the LSs was measured using nitrogen elemental analysis 
(PerkinElmer 2400 Series II CHNS/O Analyzer), which measures percent nitrogen in the 
sample. A multiplication factor of 6.25 was use to convert percent nitrogen to percent 
protein [25]. Scanning electron micrographs (SEM) of LSs before and after treatment were 
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taken to confirm the removal of the biomolecules, and to determine if chemical treatment 
causes any damage to LSs.
2.3. Filling LSs with foreign molecules
To assess the ability to fill different molecules in to LS core, dry chemically-treated LSs 
were added to respective aqueous solutions of sulforhodamine, dextran conjugated to 
fluorescein isothiocyanate, ovalbumin conjugated to texas red, bovine serum albumin 
conjugated to texas red. Vacuum of about 25 inch of Hg was applied overnight by placing 
the aqueous suspensions of LSs in a vacuum chamber. LSs were then imaged using confocal 
microscopy (Ti-E inverted microscope with C2+ point scanning confocal system, Nikon 
Melville, NY).
2.4. Vaccine formulations
Vaccine formulations were prepared as follows in 0.3 ml PBS (dose per mouse): OVA alone: 
OVA(100 μg) - dose was selected based on a previous study [26]; LS1: OVA(100 μg)+LS(1 
mg); LS5: OVA(100 μg)+LS(5 mg); CT1: OVA(100 μg)+CT(5 μg); CT2: OVA(5 mg)+CT(5 
μg). Higher dose of OVA was used because it has been shown that CT is more effective 
when OVA dose is high [26]; CTB: OVA(100 μg)+CTB(50 μg). B-subunit of CT is a safer 
mucosal adjuvant than CT, but it is less immunogenic.
2.5. Immunizations and sample collection
BALB/c female mice 6-8 weeks-old were purchased from Charles River Laboratories (MA, 
USA) and were maintained at Texas Tech University Animal Care Services (TX, USA). All 
treatments were performed according to Texas Tech Animal Care and Use Committee 
(IACUC) approved procedures. All mice were fed an OVA-free diet. Mice (n=5 per group) 
were orally immunized by administering each mouse 0.3 ml of the vaccine formulation 
(OVA alone, CT1, CT2, CTB, LS1 or LS5) using a 27G blunt-tipped feeding needle. In a 
separate experiment, to examine the effect of neutralization of gastric acid prior to oral 
vaccination, mice were deprived of food and water 2 h prior to the immunizations. Next they 
were given an oral gavage of 0.3 ml of sodium bicarbonate (8 parts PBS + 2 parts 0.34 M 
sodium bicarbonate) [27, 28] to neutralize the acid in their stomach, and 30 min later were 
orally immunized with OVA alone (OVA-Na group) or LS5 formulation (LS5-Na group). 
Separate groups of mice also received OVA alone or LS5 without pre-feeding with sodium 
bicarbonate. In all experiments, mice were immunized on days 0 and 28. Blood was 
collected from animals via the retro-orbital plexus on days 0, 28 and 56. Sera were stored at 
-20 °C until analysis. For the determination of mucosal immune response about 10-15 fecal 
droppings were collected from each animal, processed in PBS, and the saline extracts were 
stored at -20 °C until analysis. For measuring the long term immune response, in some 
groups serum and fecal matter were also collected at 7 months after first oral dose (day 0).
2.6. Antibody measurement
OVA-specific antibodies in (i) pooled sera diluted from 1:50 to 1:6400, (ii) individual 
mouse sera at a dilution of 1:200, 1:400, or 1:25, and (iii) fecal samples at an individual 
dilution of 1:5 were analyzed by standard ELISA. The wells of a 96-well plate (Maxisorp-
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Nunc, Sigma-Aldrich, MO, USA) were coated with 50 μl of 5 μg/ml OVA solution in PBS 
and kept overnight at 4°C. The wells were then blocked using 100 μl of milk (5% in PBS 
containing 0.05% tween 20) for 1.5 h at room temperature. Pooled serum samples from each 
group were serially diluted (from 1:50 to 1:6400), added (50 μl) in the wells of the plate, and 
incubated at room temperature for 1.5 h. Secondary antibody (HRP-conjugated goat anti-
mouse IgG) at a dilution of 1:4000 was then added to the wells and incubated for 1.5 h at 
room temperature. The plate was washed three times with PBS containing 0.05% tween 20 
between each step, using the ELx405 microplate washer (BioTek, VT, USA). 50 μl OPD 
solution was finally added in the wells and incubated for 15 min at room temperature. The 
reaction was stopped by adding 50 μl sulfuric acid to each well. The plate was read at 490 
nm using a microplate reader (SpectraMax Plus384, Molecular Devices LLC, Sunnyvale, 
CA). Optical Density (OD) at each dilution was determined to obtain a titration curve.
Using the titration curve a suitable dilution was selected and samples from individual 
animals for all groups were then diluted to this value, and the OD for individual animals was 
determined. Pooled serum samples at the same dilution were used to determine the IgG 
isotypes in serum. Similarly, serum samples from individual animals were diluted at 1:25 
and analyzed by ELISA to determine anti-OVA IgE. Fecal samples at an individual dilution 
of 1:5 were analyzed by ELISA to determine anti-OVA IgA using the same procedure as 
described above.
2.7. Evaluation of the ability of LSs to cross intestinal epithelium
Mice (n=3) were fed 5 mg of treated LSs, euthanized 24 h later, their intestines were 
isolated, cleaned, cut into small pieces, further cut longitudinally to expose the intestinal 
epithelium, laid flat between a cover slip and glass slide with the cover slip touching the 
epithelial surface, and visualized using confocal microscopy. LSs are naturally fluorescent 
over a broad emissionspectrum but were better visible under TRITC (570 nm) filter. 
Verification of the confocal microscopy technique to identify LSs and discriminate their 
presence on epithelial or serosal surfaces is presented in Supplementary Information-
Materials and Methods.
2.8. Statistical analysis
All statistical analysis was performed using GraphPad Prism for Windows version 6.0 
(GraphPad Software, Inc., CA, USA). Comparison of antibody levels between groups of 
mice was performed with a two-way analysis of variance (ANOVA) and a Tukey test of 
multiple comparisons at a value of p < 0.05 for statistical significance.
3. Results and Discussion
3.1. Creating intact LSs with a clean core
PGs are natural microparticles that plants use for safe transportation of their genetic 
material, often across large geographical distances with fluctuating climatic conditions. To 
perform this function, the pollen wall typically comprises of two main layers, the outer exine 
and the inner intine. Exine is composed of a tough biopolymer called sporopollenin, which 
is resistant to acetolysis, high temperature and decay, while intine is mostly made of 
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cellulose and pectin [29]. Exine, is highly permeable [30] and the pores of the exine wall, 
which can be up to 40 nm wide, allow for the penetration of different substances into the 
central hollow core of pollens [21, 31, 32].
We postulated that the naturally-occurring pores in the pollen wall could be used to allow 
chemicals to penetrate the pollen core to facilitate removal of the intine layer, and 
biomolecules such as cellular organelle, proteins and lipids, and then could subsequently be 
used to load vaccine molecules in to the clean pollen core for oral delivery (Fig 1). PG size 
and shape varies from one plant species to another as can be seen from the scanning electron 
micrographs of PGs from four different plant species (Fig 2A-2D). However, within a plant 
species PGs possess size and morphological homogeneity as exemplified by LSs (Fig 2E). 
In this study we selected LSs as the model system and sequentially treated them with 
acetone, potassium hydroxide, and phosphoric acid; to dissolve lipids and hydrophobic 
molecules, proteins and cellulosic intine layer, respectively. By comparing unprocessed and 
processed LSs (Fig 2E vs 2F; 2G vs 2H; 2I vs 2J) it can be seen that the chemical treatment 
does not damage the LSs. Furthermore, comparing Fig 3A to 3B it can be qualitatively seen 
that the chemical treatment removes native biomolecules from the LS core. We also 
quantified the final protein concentration in the treated pollen to be 0.53% (w/w of pollen) 
as compared to 7.3% in untreated raw LSs, resulting in about 90% removal of proteins. It is 
important to note that protein concentration was determined by assuming that the entire 
amount of measured nitrogen originates from proteins, however, nitrogen may very well be 
part of the sporopollenin chemical structure. Thus, it is likely that our calculation 
underestimates the extent of protein removal, and in fact even lower amount of protein is 
expected to remain.
We expect chemically-treated clean LSs to be non-allergenic because native proteins and 
lipids found in PGs, which are the root cause of pollen allergies [33] are removed after 
chemical treatment. Despite this, it is important to consider if treated pollens might still 
cause allergies in patients known to have pollen allergies. In this regard, some studies [34, 
35] have shown that even raw-unprocessed pollen when fed to patients of pollen hay fever 
did not present any systemic or gastrointestinal clinical symptoms. More so, oral delivery of 
pollen extracts, which contains allergens, to pollen allergy patients [36] did not result in oral 
hyposensitization, suggesting safety of pollens even in allergic subjects. Considerable 
anecdotal evidence also exists on the safety of oral uptake of PGs in their natural raw form 
without any chemical treatment. For example bee pollen and other pollen species are often 
used as a health supplement [37]. PGs and LSs are also part of traditional medicine across 
the world including India, China, American Indians, Turkish folk medicine, and Papua New 
Guniea to name a few [38]. While more thorough investigation is needed, this evidence 
suggests that chemically-treated pollens should be clinically acceptable and safe for oral 
ingestion without causing any allergies.
3.2. Filling the LS core with foreign molecules
After creating clean empty LSs we utilized the pores in their walls to fill different molecules 
in to their core by incubating LSs in aqueous solutions of fluorescently-labeled compounds 
and applying mild vacuum to facilitate removal of air from the LS core causing an ingress of 
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dissolved molecules from the outer aqueous environment into the LS core. To verify 
encapsulation, LSs were imaged using a confocal microscope. LSs are naturally fluorescent 
over a wide range of emission wavelengths from blue to red. Using appropriate combination 
of excitation-emission filters both the pollen shell and the inner core was visualized. Treated 
but empty shell can be seen in Fig 3C, and they possess a non-fluorescent interior. Figs 3D, 
3E, 3F, 3G, and 3H show treated LSs that are filled with sulforhodamine (558 Da), dextran 
(4 kDa), OVA (45 kDa), bovine serum albumin (67 kDa), and dextran (2000 kDa), 
respectively. This result is consistent with a recent study that successfully encapsulated oils, 
fats and proteins such as β-galactosidase (540 kDa) and horseradish peroxidase (100 kDa) in 
LSs [23]. Thus, a wide range of molecules can be filled in to LS core demonstrating the 
flexibility of the platform for vaccine delivery.
For the purpose of vaccination, OVA was used as an antigen. It is important to note that 
each oral dose comprised of 0.3 ml of OVA (100 μg) solution with 5 mg LSs suspended in 
it. Not all of the OVA was encapsulated in LSs because the OVA solution was in excess; it 
was present in the hollow core of LSs and their exterior. The excess solution helped to 
maintain equilibrium between OVA inside and outside the LSs, and kept them filled with 
OVA at all times.
3.3. Immune response after oral vaccination with LSs
3.3.1. Systemic immune response—To evaluate the potential of LSs for oral 
vaccination, we immunized Balb/c mice with OVA-filled LS formulations. CT and its B 
subunit (CTB) are well known adjuvants for oral immunization, and were used as positive 
controls, while OVA alone served as the negative control. After two doses (day 0 and 28), 
the antibody titration curve of day 56 pooled serum samples (Fig 4A) shows that OVA by 
itself is poorly immunogenic while addition of 5 mg LSs (LS5 group) to the formulation 
stimulated the highest antibody levels at all dilutions. Based on the dilution curve, a suitable 
dilution (1:200) was selected to analyze OVA-specific immunoglobulin G (IgG) response 
for individual mice to assess intergroup variability. From Fig 4B it can be seen that the LS5 
group elicits significantly higher anti-OVA IgG response compared to use of CT and CTB 
(p<0.0001). Although, CT1, CT2, CTB, and LS1 groups produced an increase in anti-OVA 
IgG response compared to OVA alone, it was not statistically significant (p>0.05). A dose-
dependent effect of LSs was seen wherein 5 mg LSs in the formulation stimulated a 
significantly higher (p=0.0005) anti-OVA IgG response in serum compared to 1 mg LSs 
(LS1 formulation).
We further determined Th1 and Th2 bias induced by the vaccine formulations by measuring 
serum anti-OVA IgG1 and IgG2a antibody subtypes. LS5 formulation was seen to induce 
high anti-OVA IgG1 antibody levels compared to IgG2a subtype (Fig 4C), indicating a Th2-
biased immune response. The same trend was exhibited by CT1, CT2 and CTB 
formulations, which is in agreement with previous studies reporting higher Th2 (IgG1) 
response than Th1 (IgG2a) response [39] through use of these adjuvants.
We also evaluated whether the LS5 formulation stimulates IgE antibody. Day 56 serum 
samples from individual animals at 1:25 dilution were analyzed through ELISA. We 
compared the LS5 formulation with, OVA alone and OVA with CT (CT2 formulation) as 
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the negative control and positive control groups, respectively. Analysis of serum samples 
with ELISA showed low anti-OVA IgE for all the groups (Fig 4E), and no statistically 
significant difference was observed between LS5, CT2 and OVA groups.
3.3.2. Mucosal immune response—Mucosal surfaces act as portals of entry for 
pathogens. The human body produces immunoglobulin A (IgA) at these surfaces, which can 
bind invading pathogens and can prevent them from entering systemic circulation. Hence, it 
is beneficial for a vaccine to produce a mucosal immune response in addition to a systemic 
immune response [1, 2]. Thus, we investigated stimulation of anti-OVA IgA in intestinal 
secretions. We compared the LS5 formulation (since it induced maximum serum IgG 
stimulation), OVA alone or with CT as adjuvant (CT2 formulation) as the negative and 
positive control groups, respectively. Analysis of saline extracts of fecal droppings through 
ELISA showed that (Fig 4D) on day 28 while the LS5 group exhibited a small increase in 
anti-OVA IgA, it was not statistically significant (p > 0.05). However, following a booster 
dose on day 28, the LS5 group demonstrated a significant increase in anti-OVA IgA 
compared to CT2 formulation (p = 0.0411) and OVA alone (p = 0.0013).
3.4. Effect of neutralization of gastric acid on anti-OVA antibody response
Degradation of an antigen in the hostile gastric environment is a common problem 
associated with oral vaccines. One way to deal with this problem is to neutralize the gastric 
acid to create a favorable environment in which the antigen can survive [27, 28]. The 
commercial rotavirus vaccine employs this strategy to enhance vaccine efficacy [40]. We 
thus sought to determine whether neutralizing the stomach acid prior to oral vaccination 
with LSs might further enhance the immune response. Since LS5 formulation was found to 
be the most successful formulation in the previous experiment, we focused on it to evaluate 
the gastric neutralization effect. Based on an ELISA performed on day 56 pooled sera (Fig 
5A) it was seen that pre-neutralization of gastric acid did not affect serum anti-OVA IgG 
levels for both OVA alone and LS5 formulations. This result was further confirmed through 
analysis of OVA-specific IgGs in individual mice serum (Fig 5B), wherein again no 
significant difference (p>0.05) was observed between LS5 and LS5-Na formulations. Fig 5B 
also shows that LS5 formulation (with and without gastric neutralization) produces a 
significantly (p<0.0001) higher anti-OVA IgG response compared to OVA alone (with and 
without gastric neutralization) reaffirming the effectiveness of LSs for oral vaccination. As 
seen in Fig 5C, an elevated IgG1 response compared to IgG2a was seen for both LS5 and 
LS5-Na groups, indicating that pre-neutralization of gastric acid does not change the 
character of LS-induced immune response.
3.5. Duration of anti-OVA serum and mucosal antibodies
Persisting antigen-specific antibodies are needed to maintain long-term humoral immunity 
[41]. Commercial vaccines induce high titers of antigen-specific antibodies, which either 
persist over a long time, or periodical booster doses must be administered to maintain them 
at high levels for sustained protection. For example, hepatitis B vaccine given during 
childhood is expected to provide life-long immunity [42], while the tetanus vaccine requires 
a booster dose every 10 years [43]. Thus we sought to determine if LSs could induce long 
term circulating and mucosal antibodies. We analyzed the serum and fecal droppings of 
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animals at month 7 following two oral vaccine doses at day 0 and day 28. From Fig 6A it 
can be seen that anti-OVA serum IgG and fecal IgA antibodies could be measured in the 
animals even seven months after the first vaccine dose at statistically significant levels (IgG: 
p=0.0263; IgA: p=0.0018). Furthermore, no change in IgG1 versus IgG2a bias was observed 
(Fig 6B) suggesting no long term change in the character of the immune response. Overall, 
this shows that LSs have the potential to induce long-term systemic and mucosal immune 
responses.
3.6. Penetration of LSs across the intestinal epithelium
To better understand how LSs stimulate systemic and mucosal immune responses, we 
investigated their ability to penetrate the mucosal epithelium. Mice (n=3) were fed LSs, and 
24 h later parts of their intestine (after washing) were imaged using a confocal microscope. 
Fig 7 shows that LSs can translocate in to the intestinal wall, suggesting that LSs could 
perhaps carry the antigen enabling its interaction with the local population of immune cells 
to stimulate an antigen-specific immune response. LSs due to their particulate form are also 
expected to stimulate immune cells. Similar translocation of LSs was observed in the other 
two mice (see supplementary Fig S3). LSs are approximately 25 μm in size. Previous studies 
investigating oral transport of particles have determined that particles approximately 2 μm or 
less are appropriately-sized for uptake via M-cells of the Peyer's patches [44]. However, the 
same study also reported uptake of 20 μm diameter particles, although with reduced 
frequency. Furthermore, others have reported uptake of larger particles across the intestinal 
wall [45], including that of LSs in human subjects [18]. Uptake of larger particles (>10 μm) 
is thought to occur via the villous epithelium as opposed to M-cells [46], and this 
phenomenon has been termed ‘persorption’ [47]. It is likely that LSs penetrate the villous 
epithelium via persorption, a phenomenon not yet clearly understood. Although, the current 
study demonstrates ability of LSs to penetrate the intestinal wall, additional questions 
remain to be answered, for example, what is the mechanism by which LSs stimulate the 
immune response, how efficient is the co-transport of antigens with LSs, whether the 
vaccination approach translates successfully to other sub-unit vaccines, and whether other 
pollens exhibit a similar adjuvant effect. Our laboratory is performing experiments to answer 
these questions.
3.7. Discussion on overall potential of LSs for oral vaccination
In this study we show that LSs elicit anti-OVA antibodies in serum (IgG) and intestinal 
secretions (IgA) at levels significantly higher than use of CT as an adjuvant, and these 
antibodies persisted up to seven months. LSs also induced anti-OVA IgE levels, which were 
not significantly different from those obtained by OVA alone or OVA (5 mg) + CT (5 μg). 
These findings are significant because they suggests that LSs could be a viable alternative to 
CT for oral vaccine development. CT is considered a highly effective oral adjuvant, albeit 
it's inherent toxicity prevents it from being used in humans [6]. LSs on the other hand are 
more effective and potentially safer. Clearly, use of 1 mg LSs can match the immune 
response produced by CT2 (5 mg of OVA + 5 μg of CT) with just 1/50th of the OVA dose 
(100 μg). By increasing the LS dose to 5 mg, the immune response was further significantly 
improved. LSs are relatively inexpensive, ∼ $0.2/g (Sigma Aldrich), and could be even 
cheaper if obtained in bulk. To formulate vaccine antigens with LSs, organic solvents or 
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other processing conditions that could damage the vaccine are also not required. Instead just 
mild application of vacuum is needed. This LS-filling step could be easily integrated into the 
existing vaccine manufacturing process without significant expenditure or re-engineering for 
each vaccine. Because LSs can be filled with a broad range of molecules they offer a 
modular approach of vaccine delivery via the oral route, much like a hypodermic needle, 
which offers complete flexibility over the type of vaccine to be injected. Because, 
hypodermic needles, syringes or additional devices would not be required anymore, the 
overall cost may be even lower than current vaccine prices. For developing nations this 
would also help in reducing the extraordinary burden they face for safe disposal of used-
needle medical waste [48]. More broadly, LS-based oral vaccination technology could offer 
a child-friendly and painless formulation that could potentially be available over the counter 
for self-administration.
4. Conclusion
We propose the novel concept that PGs can be engineered for oral vaccination. LSs were 
chemically cleaned to produce intact empty spores, which could be filled with foreign 
molecules up to 2000 kDa in size. LSs filled with OVA as a model antigen were used for 
oral immunization. LS5 formulation with 5 mg spores enabled stimulation of a strong anti-
OVA IgG (systemic) and IgA (mucosal) antibody response, which was higher than that 
produced by use of CT and its B subunit - CTB as oral mucosal adjuvants. The amounts of 
anti-OVA IgG and IgA produced by the LS5 formulation were not affected by pre-
neutralization of the gastric acid at the time of immunization. Furthermore, OVA-specific 
IgG and IgA antibodies were seen to persist in the mice for a prolonged period of time up to 
seven months. Confocal microscopy of intact intestinal tissues demonstrated the presence of 
LSs in the intestinal wall suggesting that translocation of LSs across the intestinal epithelium 
may be involved in stimulation of the immune system. Overall this study demonstrates the 
potential of LSs for development of oral vaccines, which could have wide applicability since 
a broad spectrum of antigens could potentially be loaded in to LSs for oral vaccination.
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Fig 1. Schematic illustrating concept of pollens as a system for oral vaccination
(A) A raw pollen grain with a naturally porous pollen wall. The pollen wall is often coated 
with a sticky material called pollen kit, which can contain allergens. PW: pollen wall, PK: 
pollen kit, CO&B: cellular organelle and biomolecules. (B) A chemically processed pollen 
grain whose native biomolecules, cellular organelle, pollen kit, and intine have been 
removed to produce an intact pollen with a clean core. (C) Pollen grain whose core is filled 
with a foreign molecule via the natural pores in the pollen wall, enabling use of pollens as 
drug and vaccine carriers.
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Fig 2. Unprocessed and chemically processed pollens
Scanning electron micrographs of unprocessed raw pollens showing diversity in shape, size 
and morphology: (A) Chenopodium album (lambs quarters) pollen grain, (B) Helianthus 
annuus (sunflower) pollen grain, (C) Artemisia vulgaris (mugwort) pollen grain, (D) Alnus 
glutinosa (alder black) pollen grain, and (E) Lycopodium clavatum (clubmoss) spore. 
Scanning electron micrographs of lycopodium spores before and after chemical processing: 
(E:before, F:after) low magnification images showing en bloc comparison, (G:before, 
H:after) higher magnification comparison of proximal face of the spore and its trilete scar 
(indicated by arrow), and (I:before, J:after) higher magnification comparison of distal face 
of the spore and its decorative ornamentation. No visible damage to the trilete scar or the 
surface ornamentation is seen after chemical processing.
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Fig 3. Interior of lycopodium spore at different stages of processing
Scanning electron micrographs of lycopodium spores manually cracked (A) before 
processing showing cellular organelle and biomolecules in the core, and (B) after chemical 
processing showing a clean core. Confocal micrographs of chemically-processed 
lycopodium spores that are (C) empty, (D) filled with sulforhodamine (558 Da), (E) filled 
with dextran conjugated to fluorescein isothiocyanate (4000 Da), (F) filled with ovalbumin 
conjugated to texas red (45,000 Da), (G) filled with bovine serum albumin conjugated to 
texas red (67,000 Da), and (H) filled with dextran conjugated to fluorescein isothiocyanate 
(2,000,000 Da).
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Fig 4. Systemic and mucosal immune response against ovalbumin (OVA) with lycopodium 
spores as the oral vaccination system
Groups of mice (n=5 per group) were orally vaccinated on days 0 and 28 with OVA and 
different adjuvants. Anti-OVA IgG and IgA were determined in serum and fecal droppings, 
respectively. (A) Titration curve of pooled day 56 mouse serum demonstrating the high anti-
OVA IgG stimulated with 5 mg LSs (LS5 group) in comparison to all other formulations. 
(B) Anti-OVA IgG in individual mouse serum (diluted 1:200) at different time point (days 0, 
28 and 56). LS5 group shows significantly higher antibody response compared to all groups. 
Each symbol represents a mouse, the error bar represents standard deviation, and the 
horizontal line represents the mean. (C) Anti-OVA IgG subtypes in day 56 pooled serum 
(dilution 1:200). Error bars indicate standard deviation. (D) Anti-OVA IgA in individual 
mouse fecal droppings (diluted 1:5) at different time points (days 0, 28 and 56). LS5 group 
shows significantly higher antibody response compared to OVA alone. Each symbol 
represents a mouse, the error bar represents standard deviation, and the horizontal line 
represents the mean. (E) Anti-OVA IgE in day 56 individual mouse serum (diluted 1:25). 
LS5 group does not show any statistically significant difference as compared to OVA and 
CT2 groups. ns: not statistically significant (p>0.05).
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Fig 5. Effect of gastric acid neutralization on stimulation of ovalbumin-specific serum IgGs
Groups of mice (n=5 per group) were fed sodium bicarbonate buffer before orally 
administering ovalbumin (OVA)-based vaccine formulations. Vaccinations were performed 
on days 0 and 28, and serum samples were analyzed to determine anti-OVA IgG. (A) 
Titration curve of day 56 pooled mouse serum demonstrating the high anti-OVA IgG 
stimulation from groups receiving OVA with 5 mg LSs either with (LS5-Na group) or 
without (LS5 group) sodium bicarbonate pre-feed. No effect of gastric acid neutralization is 
seen. (B) Anti-OVA IgG in individual mouse serum at days 0 and 56 at a dilution of 1:400. 
Both LS5 and LS5-Na groups show significantly higher anti-OVA IgG response compared 
to OVA alone administered either with (OVA-Na group) or without (OVA group) sodium 
bicarbonate pre-feed. No significant difference is observed between LS5 and LS5-Na groups 
(p>0.05). Each symbol represents a mouse, the error bar represents standard deviation, and 
the horizontal line represents the mean. ns: not statistically significant. (C) Anti-OVA IgG 
subtypes in day 56 pooled serum samples (diluted 1:400). Error bars indicate standard 
deviation.
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Fig 6. Long term systemic and mucosal immune response
Groups of mice (n=5 per group) were orally vaccinated on days 0 and 28 with OVA, with or 
without 5 mg lycopodium spores. Serum and fecal droppings were collected seven months 
later and analyzed to determine anti-OVA IgG and IgA. (A) Anti-OVA IgG in individual 
mouse serum (diluted 1:400), and anti-OVA IgA in individual mouse fecal droppings 
(diluted 1:5). Use of 5 mg LSs (LS5 group) results in elevated IgG and IgA levels even 
seven months after vaccination (IgG: p=0.0263; IgA: p=0.0018). Each symbol represents a 
mouse, the error bar represents standard deviation, and the horizontal bar represents the 
mean. (B) Anti-OVA IgG subtypes in month seven pooled serum samples (diluted 1:400). 
Error bars indicate standard deviation.
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Fig 7. Penetration of LSs across intestinal epithelium in to the intestinal wall
Mice (n=3) were fed 5 mg LSs, and 24 h later their intestinal tissues were imaged using a 
confocal microscope. Representative confocal micrographs at serosal surface, interior part of 
intestinal wall, and epithelial surface are shown. Presence of LSs in inner parts of the wall 
demonstrates that LSs can cross the epithelial surface and enter the intestinal wall.
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